Abhisheak Sharma, M.Pharm., Ph.D.
Director And Assistant Professor
About Abhisheak Sharma
Abhisheak Sharma is a Co-Director of Translational Drug Development Core and Assistant Professor at University of Florida, Gainesville. He received his B. Pharm. from the Mohan Lal Sukhadia University, Udaipur, India in 2006 and became a registered pharmacist in India. He received his M. Pharm. in pharmaceutical chemistry from U. P. Technical University, Lucknow, India with a MHRD-Post-graduate fellowship (2006-2008) by All India Council for Technical Education (AICTE). He earned his Ph.D. in pharmacokinetics & metabolism from CSIR-Central Drug Research Institute, Lucknow, India. He was awarded Senior Research Fellowship during his graduate studies (2011-2015) by Indian Council of Medical Research (ICMR). After his graduate studies, Dr. Sharma did his post-doctoral research under the supervision of Dr. Bonnie A. Avery at the University of Mississippi (2015-2017) and University of Florida (2017-2019).
Accomplishments
Media Excellence Award
2024
·
UF College of Pharmacy
UF/IFAS High Impact Research Publication Award
2021
·
UF-Institute of Food and Agricultural Sciences (IFAS)
Champions of CUR
2020
·
UF Center for Undergraduate Research
Translational Research in Addiction Travel Award
2017
·
Behavior, Biology, and Chemistry
Novartis Travel Award for Uppsala Pharmacometric Summer School
2014
·
Novartis
Senior Research Fellowship
2011-2015
·
Indian Council of Medical Research, Ministry of Health and Family Welfare
MHRD-Post-graduate fellowship
2006-2008
·
All India Council for Technical Education
Teaching Profile
Courses Taught
2020-2024
GMS6009 Principles of Drug Action and Therapeutics
2021-2025
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2022-2024
PHA6416 Pharmaceutical Analysis I
2022-2024
PHA7980 Research for Doctoral Dissertation
2022-2024
PHA6935 Selected Topics in Pharmacy
2023-2025
PHA7979 Advanced Research
2023-2025
PHA6185 Life Cycle of a Drug
2023-2024
PHA6910 Supervised Research
2023-2024
PHA6125 Introduction to Quantitative Pharmacology
2024
PHC6722 Environmental and Global Health Research Methods Rotation
2024
PHA6468 Biotransformation Considerations in Drug Design
Research Profile
Abhisheak Sharma’s research focuses on the in vivo and in vitro preclinical pharmacokinetic studies of new chemical entities and natural products. He is proficient in various approaches to bioanalytical method development and validation of discovery compounds and plant alkaloids in different biological matrices (blood, dried blood spot, plasma, serum, tissue homogenates, and urine) using various analytical techniques (UPLC-MS/MS, UPLC-PDA-MS, and UPLC-PDA/FL). His research interests include translational development of new chemical entities to candidate drugs using PK-PD modeling and simulation approach. Dr. Sharma published more than sixty peer-reviewed articles in highly respected journals and one book chapter in the field of pharmacokinetics and drug discovery. His research interests include: pharmacokinetics, drug development, drug-drug interaction, pharmacokinetic modeling and simulation
Areas of Interest
- Bioanalysis
- Drug Metabolism
- Pharmacokinetics
- Pharmacokinetics/pharmacodynamics
- Population pharmacokinetics
Publications
Academic Articles
2024
An update on the clinical pharmacology of kratom: uses, abuse potential and future considerations
Expert Review of Clinical Pharmacology.
17(2):131-142
[DOI] 10.1080/17512433.2024.2305798.
[PMID] 38217374.
2024
C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models
Journal of Clinical Investigation.
[DOI] 10.1172/jci177429.
2024
Commercial Delta-8 THC Products: an Analysis of Content and Labeling.
Journal of medical toxicology : official journal of the American College of Medical Toxicology.
20(1):31-38
[DOI] 10.1007/s13181-023-00974-y.
[PMID] 37917314.
2024
Effects of kratom on driving: Results from a cross-sectional survey, ecological momentary assessment, and pilot simulated driving Study.
Traffic injury prevention.
25(4):1-10
[DOI] 10.1080/15389588.2024.2327827.
[PMID] 38497810.
2024
Explorations of Agonist Selectivity for the α9* nAChR with Novel Substituted Carbamoyl/Amido/Heteroaryl Dialkylpiperazinium Salts and Their Therapeutic Implications in Pain and Inflammation.
Journal of medicinal chemistry.
67(11):8642-8666
[DOI] 10.1021/acs.jmedchem.3c02429.
[PMID] 38748608.
2024
Fatty acid binding protein 7 plays an important modulatory sex-dependent role on brain endocannabinoid levels and THC metabolism
PLOS ONE.
19(12)
[DOI] 10.1371/journal.pone.0313091.
[PMID] 39621669.
2024
Fatty acid-binding protein 7 gene deletion promotes decreases in brain cannabinoid type 1 receptor binding.
Neuroscience letters.
844
[DOI] 10.1016/j.neulet.2024.138040.
[PMID] 39542341.
2024
Formation of multiple ion types during MALDI imaging mass spectrometry analysis of Mitragyna speciosa alkaloids in dosed rat brain tissue
Talanta.
274
[DOI] 10.1016/j.talanta.2024.125923.
[PMID] 38569366.
2024
Microbiome and Otic Quinolone Levels Following Tympanoplasty Assessed by Gelatin Sponge Analysis.
Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
171(2):400-407
[DOI] 10.1002/ohn.722.
[PMID] 38529675.
2024
Multimodal Image Fusion Workflow Incorporating MALDI Imaging Mass Spectrometry and Microscopy for the Study of Small Pharmaceutical Compounds.
Analytical chemistry.
96(29):11869-11880
[DOI] 10.1021/acs.analchem.4c01553.
[PMID] 38982936.
2024
Multiple-Dose Pharmacokinetics and Safety of Mitragynine, the Major Alkaloid of Kratom, in Rats.
ACS pharmacology & translational science.
7(8):2452-2464
[DOI] 10.1021/acsptsci.4c00277.
[PMID] 39144552.
2024
Perinatal Nicotine Vaping Exposure Induces Pro-myofibroblastic Phenotype in Rat Bone Marrow-derived Mesenchymal Stem Cells
Reproductive Toxicology.
129
[DOI] 10.1016/j.reprotox.2024.108673.
[PMID] 39059775.
2024
Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats
Pharmaceutics.
16(3)
[DOI] 10.3390/pharmaceutics16030318.
[PMID] 38543213.
2024
Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid
Drug Testing and Analysis.
[DOI] 10.1002/dta.3703.
[PMID] 38747129.
2024
Responses to a “Typical” Morning Dose of Kratom in People Who Use Kratom Regularly: A Direct-Observation Study.
Journal of addiction medicine.
18(2):144-152
[DOI] 10.1097/ADM.0000000000001259.
[PMID] 38174871.
2024
Separate gut-brain circuits for fat and sugar reinforcement combine to promote overeating
Cell Metabolism.
36(2):393-407.e7
[DOI] 10.1016/j.cmet.2023.12.014.
[PMID] 38242133.
2024
Separate gut-brain circuits for fat and sugar reinforcement combine to promote overeating.
Cell metabolism.
36(6)
[DOI] 10.1016/j.cmet.2024.05.004.
[PMID] 38761797.
2024
Synthesis of α3β4 Nicotinic Acetylcholine Receptor Modulators Derived from Aristoquinoline That Reduce Reinstatement of Cocaine-Seeking Behavior.
Journal of medicinal chemistry.
67(1):529-542
[DOI] 10.1021/acs.jmedchem.3c01758.
[PMID] 38151460.
2024
The rise of novel, semi‐synthetic 7‐hydroxymitragnine products
Addiction.
[DOI] 10.1111/add.16728.
[PMID] 39627873.
2024
Time course of kratom effects via ecological momentary assessment, by product type, dose amount, and assayed alkaloid content.
Drug and alcohol dependence.
264
[DOI] 10.1016/j.drugalcdep.2024.112460.
[PMID] 39405600.
2023
An ethogram analysis of cutaneous thermal pain sensitivity and oxycodone reward-related behaviors in rats
Scientific Reports.
13(1)
[DOI] 10.1038/s41598-023-36729-6.
[PMID] 37380739.
2023
Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products
European Journal of Drug Metabolism and Pharmacokinetics.
48(4):427-435
[DOI] 10.1007/s13318-023-00839-3.
[PMID] 37337087.
2023
FABP5 is important for cognitive function and is an important regulator of the physiological effects and pharmacokinetics of acute Δ9 tetrahydrocannabinol inhalation in mice
Pharmacology Biochemistry and Behavior.
231
[DOI] 10.1016/j.pbb.2023.173633.
[PMID] 37716413.
2023
Kratom Alkaloids: A Blueprint?
ACS chemical neuroscience.
14(2):195-197
[DOI] 10.1021/acschemneuro.2c00704.
[PMID] 36594896.
2023
Kratom Withdrawal: Discussions and Conclusions of a Scientific Expert Forum
Drug and Alcohol Dependence Reports.
7
[DOI] 10.1016/j.dadr.2023.100142.
[PMID] 37397437.
2023
Metabolite and Molecular Characterization of Mitragyna speciosa Identifies Developmental and Genotypic Effects on Monoterpene Indole and Oxindole Alkaloid Composition
Journal of Natural Products.
86(4):1042-1052
[DOI] 10.1021/acs.jnatprod.3c00092.
[PMID] 36913648.
2023
Not all kratom is equal: The important distinction between native leaf and extract products.
Addiction (Abingdon, England).
119(1):202-203
[DOI] 10.1111/add.16366.
[PMID] 37814405.
2023
Novel methods for the remote investigation of emerging substances: Application to kratom.
Experimental and clinical psychopharmacology.
32(2):215-227
[DOI] 10.1037/pha0000656.
[PMID] 37213182.
2023
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research.
29(9):1751-1762
[DOI] 10.1158/1078-0432.CCR-22-1682.
[PMID] 36749885.
2023
Pharmacokinetic and Pharmacodynamic Consequences of CYP3A Inhibition on Mitragynine Metabolism in Rats
Journal of Pharmacology and Experimental Therapeutics.
385(3):JPET-AR
[DOI] 10.1124/jpet.122.001525.
[PMID] 37019472.
2023
Pharmacokinetics of delta-9-tetrahydrocannabinol following acute cannabis smoke exposure in mice; effects of sex, age, and strain.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1227220.
[PMID] 37701025.
2023
Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders
Current Addiction Reports.
[DOI] 10.1007/s40429-023-00472-9.
2023
Vaporized Delta-9-tetrahydrocannabinol Inhalation in Female Sprague Dawley Rats: A Pharmacokinetic and Behavioral Assessment.
Current pharmaceutical design.
29(27):2149-2160
[DOI] 10.2174/1381612829666230419093809.
[PMID] 37114788.
2023
What Is the Kratom Overdose Risk? A Systematic Literature Review
Current Addiction Reports.
[DOI] 10.1007/s40429-022-00464-1.
2022
Acute Renal Insufficiency Associated With Consumption of Hydrocodone- and Morphine-Adulterated Kratom (Mitragyna Speciosa).
The Journal of emergency medicine.
63(1):e28-e30
[DOI] 10.1016/j.jemermed.2022.02.004.
[PMID] 35940982.
2022
Characterization of Different Forms of Kava (Piper methysticum) Products by UPLC-MS/MS.
Planta medica.
88(14):1348-1359
[DOI] 10.1055/a-1708-1994.
[PMID] 34839465.
2022
Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers.
Journal of ethnopharmacology.
297
[DOI] 10.1016/j.jep.2022.115514.
[PMID] 35777607.
2022
In vitro and in vivo pharmacology of kratom.
Advances in pharmacology (San Diego, Calif.).
93:35-76
[DOI] 10.1016/bs.apha.2021.10.001.
[PMID] 35341571.
2022
Metabolism of Speciociliatine, an Overlooked Kratom Alkaloid for its Potential Pharmacological Effects.
The AAPS journal.
24(5)
[DOI] 10.1208/s12248-022-00736-8.
[PMID] 35854066.
2022
Plant growth and phytoactive alkaloid synthesis in kratom [Mitragyna speciosa (Korth.)] in response to varying radiance.
PloS one.
17(4)
[DOI] 10.1371/journal.pone.0259326.
[PMID] 35472200.
2022
The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study.
Drug metabolism and disposition: the biological fate of chemicals.
50(2):158-167
[DOI] 10.1124/dmd.121.000640.
[PMID] 34759012.
2022
UPLC-MS/MS method for the quantification of MCI-77, a novel sigma-1 receptor ligand, and its application to pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
1196
[DOI] 10.1016/j.jchromb.2022.123187.
[PMID] 35278810.
2022
Variations in mitragynine content in the naturally growing Kratom (Mitragyna speciosa) population of Thailand
Frontiers in Plant Science.
13
[DOI] 10.3389/fpls.2022.1028547.
[PMID] 36388525.
2021
Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors.
Journal of medicinal chemistry.
64(18):13510-13523
[DOI] 10.1021/acs.jmedchem.1c00726.
[PMID] 34467758.
2021
Acute morphine blocks spinal respiratory motor plasticity via long-latency mechanisms that require toll-like receptor 4 signalling.
The Journal of physiology.
599(15):3771-3797
[DOI] 10.1113/JP281362.
[PMID] 34142718.
2021
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder.
Expert opinion on drug metabolism & toxicology.
17(3):255-257
[DOI] 10.1080/17425255.2021.1853706.
[PMID] 33213215.
2021
Exploring the Chemistry of Alkaloids from Malaysian Mitragyna speciosa (Kratom) and the Role of Oxindoles on Human Opioid Receptors.
Journal of Natural Products.
84(4):1034-1043
[DOI] 10.1021/acs.jnatprod.0c01055.
[PMID] 33635670.
2021
Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells.
Pathogens (Basel, Switzerland).
10(11)
[DOI] 10.3390/pathogens10111514.
[PMID] 34832669.
2021
Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine.
European journal of drug metabolism and pharmacokinetics.
46(3):459-463
[DOI] 10.1007/s13318-021-00684-2.
[PMID] 33847897.
2021
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats
Journal of Natural Products.
84(4):1104-1112
[DOI] 10.1021/acs.jnatprod.0c01163.
[PMID] 33620222.
2021
Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method.
Journal of pharmaceutical and biomedical analysis.
194
[DOI] 10.1016/j.jpba.2020.113778.
[PMID] 33277117.
2020
Adolescent nicotine and tobacco smoke exposure enhances nicotine self-administration in female rats.
Neuropharmacology.
176
[DOI] 10.1016/j.neuropharm.2020.108243.
[PMID] 32702403.
2020
Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand.
Journal of pharmaceutical and biomedical analysis.
191
[DOI] 10.1016/j.jpba.2020.113610.
[PMID] 32971495.
2020
Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis.
180
[DOI] 10.1016/j.jpba.2019.113019.
[PMID] 31838282.
2020
Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo.
The AAPS journal.
22(5)
[DOI] 10.1208/s12248-020-00472-x.
[PMID] 32691179.
2020
Effects of Nutrient Fertility on Growth and Alkaloidal Content in Mitragyna speciosa (Kratom).
Frontiers in plant science.
11
[DOI] 10.3389/fpls.2020.597696.
[PMID] 33408731.
2020
Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats.
Drug and alcohol dependence.
215
[DOI] 10.1016/j.drugalcdep.2020.108235.
[PMID] 32889450.
2020
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.
Toxicology letters.
319:148-154
[DOI] 10.1016/j.toxlet.2019.11.005.
[PMID] 31707106.
2020
Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands.
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents.
29(9):1697-1706
[DOI] 10.1007/s00044-020-02597-2.
[PMID] 33584084.
2020
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
Journal of medicinal chemistry.
63(1):433-439
[DOI] 10.1021/acs.jmedchem.9b01465.
[PMID] 31834797.
2020
Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence.
Drug and alcohol dependence.
216
[DOI] 10.1016/j.drugalcdep.2020.108310.
[PMID] 33017752.
2020
Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy.
ACS pharmacology & translational science.
3(6):1063-1068
[DOI] 10.1021/acsptsci.0c00075.
[PMID] 33344889.
2020
Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Journal of ethnopharmacology.
249
[DOI] 10.1016/j.jep.2019.112462.
[PMID] 31816368.
2020
Pharmacokinetic and Biochemical Profiling of Sodium Dichloroacetate in Pregnant Ewes and Fetuses.
Drug metabolism and disposition: the biological fate of chemicals.
49(6):451-458
[DOI] 10.1124/dmd.120.000330.
[PMID] 33811107.
2020
Pharmacokinetics and Safety of Mitragynine in Beagle Dogs.
Planta medica.
86(17):1278-1285
[DOI] 10.1055/a-1212-5475.
[PMID] 32693425.
2020
Regulatory sampling of industrial hemp plant samples (Cannabis sativa L.) using UPLC-MS/MS method for detection and quantification of twelve cannabinoids.
Journal of cannabis research.
2(1)
[DOI] 10.1186/s42238-020-00050-0.
[PMID] 33526142.
2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
Oncogene.
38(22):4264-4282
[DOI] 10.1038/s41388-019-0717-6.
[PMID] 30718919.
2019
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Nature medicine.
25(12):1938-1947
[DOI] 10.1038/s41591-019-0668-z.
[PMID] 31792461.
2019
Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
1134-1135
[DOI] 10.1016/j.jchromb.2019.121875.
[PMID] 31790916.
2019
Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
Planta medica.
85(4):340-346
[DOI] 10.1055/a-0770-3683.
[PMID] 30452072.
2019
Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom).
Xenobiotica; the fate of foreign compounds in biological systems.
49(11):1279-1288
[DOI] 10.1080/00498254.2018.1552819.
[PMID] 30547698.
2019
Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry.
Drug testing and analysis.
11(8):1162-1171
[DOI] 10.1002/dta.2604.
[PMID] 30997725.
2018
A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications.
PloS one.
13(5)
[DOI] 10.1371/journal.pone.0197940.
[PMID] 29795658.
2017
A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin.
Drug development and industrial pharmacy.
43(5):847-861
[DOI] 10.1080/03639045.2016.1239732.
[PMID] 27648633.
2017
Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.
Naunyn-Schmiedeberg's archives of pharmacology.
390(9):971-976
[DOI] 10.1007/s00210-017-1401-4.
[PMID] 28689253.
2017
Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.
Drug testing and analysis.
9(8):1124-1136
[DOI] 10.1002/dta.2128.
[PMID] 27794181.
2017
Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study.
Drug testing and analysis.
9(8):1236-1242
[DOI] 10.1002/dta.2156.
[PMID] 28039926.
2017
Simultaneous LC-MS-MS Determination of Lopinavir and Rifabutin in Human Plasma.
Journal of chromatographic science.
55(6):617-624
[DOI] 10.1093/chromsci/bmx016.
[PMID] 28334925.
2016
Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes.
European journal of medicinal chemistry.
110:237-45
[DOI] 10.1016/j.ejmech.2016.01.028.
[PMID] 26840364.
2016
Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors.
Organic & biomolecular chemistry.
14(4):1338-58
[DOI] 10.1039/c5ob02113h.
[PMID] 26659548.
2016
Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
European journal of medicinal chemistry.
109:187-98
[DOI] 10.1016/j.ejmech.2015.12.038.
[PMID] 26774925.
2016
Insights into the pharmacokinetic properties of antitubercular drugs.
Expert opinion on drug metabolism & toxicology.
12(7):765-78
[DOI] 10.1080/17425255.2016.1183643.
[PMID] 27120703.
2016
LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
Bioanalysis.
8(6):533-45
[DOI] 10.4155/bio.16.7.
[PMID] 26915470.
2016
Role of enterohepatic recirculation in drug disposition: cooperation and complications.
Drug metabolism reviews.
48(2):281-327
[DOI] 10.3109/03602532.2016.1157600.
[PMID] 26987379.
2016
Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
Journal of medical toxicology : official journal of the American College of Medical Toxicology.
12(4):341-349
[PMID] 27752985.
2015
Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
20(3):231-5
[DOI] 10.3109/13625187.2015.1017756.
[PMID] 25798535.
2015
Gender-related pharmacokinetics and bioavailability of a novel anticancer chalcone, cardamonin, in rats determined by liquid chromatography tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
986-987:23-30
[DOI] 10.1016/j.jchromb.2015.01.041.
[PMID] 25703949.
2015
HPLC-MS-MS Method Development and Validation of Antileishmanial Agent, S010-0269, in Hamster Serum.
Journal of chromatographic science.
53(9):1542-8
[DOI] 10.1093/chromsci/bmv050.
[PMID] 25935158.
2015
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Bioorganic & medicinal chemistry.
23(4):742-52
[DOI] 10.1016/j.bmc.2014.12.060.
[PMID] 25614114.
2015
Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice.
Molecular pharmacology.
88(4):768-78
[DOI] 10.1124/mol.115.098376.
[PMID] 26240287.
2015
Rapid quantitative analysis of ormeloxifene and its active metabolite, 7-desmethyl ormeloxifene, in rat plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
997:7-15
[DOI] 10.1016/j.jchromb.2015.05.034.
[PMID] 26079264.
2014
Dried blood spots: concepts, present status, and future perspectives in bioanalysis.
Drug testing and analysis.
6(5):399-414
[DOI] 10.1002/dta.1646.
[PMID] 24692095.
2014
Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.
ACS medicinal chemistry letters.
5(8):878-83
[DOI] 10.1021/ml500211c.
[PMID] 25147607.
2013
Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents.
Journal of medicinal chemistry.
56(11):4374-92
[DOI] 10.1021/jm400053v.
[PMID] 23611626.
2013
Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents.
European journal of medicinal chemistry.
66:69-81
[DOI] 10.1016/j.ejmech.2013.05.023.
[PMID] 23792317.
Presentations
2022-09-24
Opioid receptor partial agonists as novel treatment approaches & formulations for pain
National
/
Invited.
Seminar.
Bethesda, MD
2022-07-20
PhD and career opportunities in pharmaceutical sciences
National
/
Invited.
Lecture.
Online
2021-11-24
A PK-PD model to understand the antinociceptive effects of mitragynine and contribution of its active metabolite, 7-hydroxymitragynine
International
/
Invited.
Seminar.
Online
2021-07-17
Pharmacokinetic methodologies for the systemic development of traditional herbal products
International
/
Invited.
Lecture.
Online
2021-01-26
Kratom–Potential drug of abuse or useful analgesic without opioid-like side-effects?
National
/
Invited.
Symposium.
Big Sky, MT
2021-01-09
Pre-clinical pharmacokinetic studies and their role in drug discovery
International
/
Invited.
Seminar.
Online
2021-12-01
Use of traditional medicines in Indian subcontinent
National
/
Invited.
Seminar.
Gainesville
2022-10-18
Pharmacokinetic-Pharmacodynamic modeling of the antinociceptive effect of mitragynine, the most abundant kratom alkaloid in mice
National
/
Invited.
Seminar.
Boston
2021-06-20
Role of pharmacokinetics in drug development process of complex natural products
International
/
Invited.
Seminar.
Online
2019-08-02
Kratom Alkaloidal Composition: Traditional Malaysian Preparation versus Commercial Products in the United States
National
/
Invited.
Seminar.
Boston
2022-11-26
Pharmacokinetics based approach for the formulation development of complex natural products
International
/
Invited.
Keynote.
2023-11-14
AAPS Communities and Opportunities: Insights from AAPS Members in Industry and Academia
National
/
Invited.
Seminar.
Gainesville, FL and Online
2023-10-24
Status of Pharmacokinetics, Pharmacodynamics, & Drug Metabolism Community
International
/
Other.
Speech.
Orlando, FL
2024-12-07
IND Enabling Studies and Translational Drug Development
International
/
Invited.
Keynote.
2024-07-15
Role of pharmacokinetics and selection of animal species for investigational new drug (IND) enabling studies
International
/
Invited.
Continuing Education.
2024-05-30
Kratom use during pregnancy and prevalence of neonatal abstinence syndrome
National
/
Invited.
Seminar.
Grants
Aug 2024
ACTIVE
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder
Role: Project Manager
Funding: SPARIAN BIOSCIENCES
via NATL INST OF HLTH NIDA
Aug 2023
– Jul 2024
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder
Role: Co-Investigator
Funding: SPARIAN BIOSCIENCES
via NATL INST OF HLTH NIDA
Apr 2023
ACTIVE
Novel therapeutic development for breast cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Mar 2023
ACTIVE
Kratom alkaloid exposure during pregnancy
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Aug 2021
ACTIVE
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
May 2021
– Feb 2023
Effects of cannabis on Alzheimers disease-related pathology and cognitive decline
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Jan 2021
ACTIVE
Developing a Novel PROTAC-Based NR4A1 Degrader for Breast Cancer Therapy
Role: Other
Funding: US ARMY MED RES ACQUISITION
Dec 2020
– Nov 2024
Opioid use disorders: UF Pharmacy medications discovery and development
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Sep 2020
ACTIVE
Opioid and cannabinoid interactions in pain and reward
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Sep 2019
– Aug 2023
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects
Role: Faculty
Funding: NATL CTR FOR COMPLEM AND INTEGRATIVE HLT
Apr 2019
ACTIVE
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Education
Ph.D.
2015
·
CSIR-Central Drug Research Institute
M.Pharm.
2008
·
U. P. Technical University
B.Pharm.
2006
·
Mohan Lal Sukhadia University
Contact Details
Phones:
- Business:
- (352) 294-8690
Emails:
- Business:
- asharma1@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100494
GAINESVILLE FL 32610 - Business Street:
-
1345 Center Drive
Medical Sciences Building
MSB P3-20B
GAINESVILLE FL 32610